Announcement PDF ABN 80 063 114 045 APPENDIX 4E and PRELIMINARY FINAL REPORT 30 JUNE 20 24 Immuron Limited Appendix 4E 30 June 2024 Immuron Limited Appendix 4E Preliminary Final Report Year ended 30 June 2024 Immuron Limited 80 063 114 045 30 June 2024 30 June 2023 Name of entity: ABN: Year ended: Previous period: Results for announcement to the market $ Revenue from ordinary activities Loss from ordinary activities after tax attributable to members Net loss for the period attributable to members Up Up Up 171.7% 83.2% 83.2% to to to 4,902,865 (6,936,957) (6,936,957) Distributions No dividends have been paid or declared by the company for the current financial year. No dividends were paid for the previous financial year. Explanation of results The reported after tax loss of the current financial year of $6,936,957 (2023: $3,786,507) is after fully expensing the company’s research and development expenditure of $5,375,461 incurred during the year (2023: $2,592,145). Of which, $2,599,458 (2023: $2,158,936) was funded by the R&D grant from Medical Technology Enterprise Consortium (MTEC). Research and development expenses increased by $2,783,316 from the financial year 2023 to 2024. The revenue from contracts with customers for the year was $4,902,865, which is an increase of 171.7% from the prior financial year (2023: $1,804,705), primarily due to the sales recovery in the Australian, U.S. and North American ® ® markets for Travelan . We anticipate that revenues from sales of our Travelan product will continue to increase in the future. As at 30 June 2024 the company’s cash position was $11,657,315 (30 June 2023: $17,159,764). The company had trade and other receivables of $1,387,573 (30 June 2023: $417,420). This receivables amount includes future receivables from the Australian Government under the R&D Tax Incentive program mentioned above. The preliminary financial report follows, with the further details to be included in the audited financial statements to be released by 30 September 2024. Immuron Limited Appendix 4E 30 June 2024 (continued) Net tangible assets per security Net tangible asset backing (per security) 2024 Cents 2023 Cents 5.51 8.53 Changes in controlled entities There have been no changes in controlled entities during the year ended 30 June 2024. Other information required by Listing Rule 4.2A a. Details of individual and total dividends or distributions and dividend or distribution payments: N/A b. Details of any dividend or distribution reinvestment plans: N/A c. Details of associates and joint venture entities: Place of business/ country of Name of entity incorporation Ownership interest held by the group 30 June 2024 30 June 2023 % % Ateria Health Limited United Kingdom 17.5 23.6 As at 30 June 2024, Immuron has a 23.61% interest in Ateria. Immuron is deemed to have significant influence over Ateria. d. Other information N/A Audit The financial statements are currently in the process of being audited. The audited financial statements along with the independent auditor report for the year end 30 June 2024 will be provided in the due course. Review of operations and activities Key highlights • Record sales of A$4.9 million for FY25 up A$3.1 million on FY23 • Immuron completes IMM-124E Phase 2 clinical trial • Immuron completes in-patient phase of CampETEC Phase 2 clinical trial • Uniformed Services University Travelan® clinical field trial reaches 77% recruitment • Immuron submits pre-IND for IMM-529 to the U.S. Food and Drug Administration (FDA) • Immuron presents at The Military Health System Research Symposium (MHSRS) • U.S. Department of Defense funds Naval Medical Research Command and Walter Reed Army Institute of Research development of enhanced formulations of Travelan® Financial review Immuron Limited has reported a loss for the financial year ended 30 June 2024 of A$6,934,691 (30 June 2023: A$3,787,519). The group's net assets decreased to A$12,709,444 compared with A$19,616,836 at 30 June 2023, including cash reserves of A$11,657,315 (30 June 2023: A$17,159,764). Record sales of A$4.9 million for FY24 up A$3.1 million on FY23 Australia: Sales of Travelan® increased to AUD $3.7 million in FY24, compared to AUD $1.1 million in FY23. Sales increased by $2.6 million (223%). Consistent with the increase in June 2024 quarter sales, the Australian Bureau of Statistics reported short term resident returns in April 2024 were 29% higher than April 20231. USA: Sales of Travelan® increased to AUD $1.1 million in FY24, compared to AUD $0.6 million in FY23. Sales increased by $0.4 million (67%). Immuron’s experience in the USA follows the International Trade Administration Total U.S. citizen international visitor departures from the United States in April 2024 being 8% higher than in April 2023.2 1. https://www.abs.gov.au/statistics/industry/tourism-and-transport/overseas-arrivals-and-departures-australia/latestrelease 2. https://www.trade.gov/us-international-air-travel-statistics-i-92-data Immuron completes IMM-124E Phase 2 clinical trial The inpatient challenge phase of the Travelan® clinical study led by Principal Investigator Dr Mohamed AlIbrahim at the Pharmaron CPC FDA inspected Clinical Research Facility Inpatient Unit located in Baltimore, Maryland US, has been completed. The double-blind study was separated into two cohorts of approx. 30 subjects (60 in total) dosed with Travelan® or placebo for two days prior to challenge and continuing dosing for a total of 7 days. All study participants were challenged with Escherichia coli, monitored for symptoms, and treated with antibiotics. Safety data at two weeks and 4 weeks post challenge has been collected and the final 6 month follow up interviews were completed. The Phase 2 clinical trial was designed to evaluate the safety and protective efficacy of Travelan® compared to a placebo in a controlled human infection model (CHIM). The primary efficacy outcome is prevention and/or reduction of moderate to severe diarrhea. ClinicalTrials.gov Identifier: NCT05933525. Topline clinical trial results demonstrate a 36.4% protective efficacy with single daily dose of Travelan® against Enterotoxigenic Escherichia coli (ETEC) induced moderate to severe diarrhea compared to the placebo group (primary endpoint) even though the attack rate for this study was 37%, much lower than the planned 70%. The attack rates on previous Phase 2 (Otto et al. 2011) were 73% and 86% with protective efficacy of 90.9% and 76.7%. There was a 43.8% reduction in diarrhea of any severity in the Travelan® group compared to the Placebo group during the 5-day period post challenge which is approaching statistical significance; p=0.066. The number of cumulative adverse events per participant in the Travelan® group (58) was statistically significantly lower than the Placebo group (109); p<0.05. The Phase 2 clinical study data also supports the excellent safety and tolerability profile of Travelan®. Immuron will now proceed to hold an end of Phase 2 meeting with the U.S Food and Drug Administration to discuss the pivotal Phase 3 registration strategy and planned clinical trials including recommended dosing to support a Biologics License Application (BLA) for Travelan® as a prophylactic medicine for Travelers’ Diarrhea. Immuron completes in-patient phase of CampETEC Phase 2 clinical trial The NMRC has recently completed the in-patient stage of the campylobacter challenge clinical study. The clinical study was led by Principal Investigator Dr Kawsar Talaat, MD at the Johns Hopkins University (JHU) Center for Immunization Research (CIR) Inpatient Unit, located at the JHU Bayview Medical Campus, Baltimore, Maryland. U.S. A total of 30 participants were enrolled in the study, of which 27 participants were dosed with either the Investigational Medical Product or placebo and all subjects were challenged with Campylobacter. All study volunteers were treated with antibiotics and discharged from the clinic. The study participants returned as outpatients for several follow-up visits, with the last patient last visit completed in June 2024. Headline results from the clinical trial are anticipated to be reported in late August 2024/early September 2024. The Phase 2 clinical trial was designed to evaluate the safety and protective efficacy of the new product manufactured by Immuron compared to a placebo in a controlled human infection model (CHIM). The primary efficacy outcome is prevention and/or reduction of moderate to severe diarrhea. ClinicalTrials.gov Identifier: NCT06122870. Uniformed Services University Travelan® clinical field trial reaches 77% recruitment USU’s Infectious Diseases Clinical Research Program (IDCRP) and the UK Ministry of Defense are jointly conducting the randomized clinical trial to evaluate the efficacy of Travelan® in Travelers’ Diarrhea. The P2TD study is a randomized, double-blind, placebo controlled multicenter clinical trial designed to evaluate the effectiveness of IMM-124E (Travelan®) passive immunoprophylaxis verses a placebo, during deployment or travel to a high-TD risk region (ClinicalTrials.gov Identifier: NCT04605783). All study participants (866 in total) will be randomized to Travelan® or placebo (433 per arm). The Problem: Travelers’ diarrhea (TD) remains a highly prevalent disease that impacts operational readiness of military personnel and is also debilitating to civilians traveling to high-risk destinations. In addition to its acute morbidity, TD is associated with acquisition of antimicrobial resistance genes and long-term sequelae. Current mitigation strategies including pre-travel counseling and antibiotics for prevention and treatment which have important limitations, and there are currently no licensed, pathogen-specific vaccines for TD prevention. The Approach: Passive immunotherapy may offer safe and relatively inexpensive preventive strategies by promoting gut resistance to enteropathogens, and potentially lessening the use of antibiotics. USU’s Infectious Diseases Clinical Research Program (IDCRP) and the UK Ministry of Defense are jointly conducting the trial to evaluate the efficacy of Travelan® for TD prevention and inform strategies for Force Health Protection. More than 77% of the target 866 study participants have been recruited. Topline results are anticipated in 1Q 2025. Immuron submits pre-IND for IMM-529 to the U.S. Food and Drug Administration (FDA) Immuron filed a pre-IND (investigational new drug) application with the United States Food and Drug Administration (FDA) for IMM-529 on 1 July 2024. The company is planning to submit a new IND to initiate the clinical development of IMM-529 for the treatment of CDI and prevention of recurrence of CDI. IMM-529 is the second therapeutic drug candidate the company has taken into the clinic and has been specifically developed to target (i) toxin B, (ii) spores and (iii) vegetative cells of Clostridioides Difficile (C. Diff) which are thought to be the primary cause of C. Diff disease recurrences. A research services agreement was executed with Monash University to assist with vaccine manufacture and stability testing of the Investigational Medical Product to support the pre-IND information package. A research services agreement was executed with VivoPharm Global Preclinical Services to conduct a GLP compliant toxicity study in rodents. The study protocol was submitted and approved by the Animal Ethics Committee and the study has been completed with no adverse findings reported. Presentation at The Military Health System Research Symposium (MHSRS) The MHSRS is the U.S. Department of Defense’s premier scientific meeting that focuses specifically on the unique medical needs of the Warfighter. This annual symposium brings together 3,000 healthcare professionals, researchers, U.S DoD leaders and decision markers as well as various funding bodies. The company attended the meeting as an Exhibitor and presented two posters at the event. One entitled ‘Clinical Evaluation of an Oral prophylactic for prevention of Travelers diarrhea in active-duty military assigned abroad.’ The company was also invited by the Medical Technology Enterprise Consortium (MTEC) to showcase Immuron and its collaborative work with the U.S. Department of Defense including an overview of the current MTEC award entitled ‘Biologics license application of a bovine immunoglobulin supplement that prevents travelers’ diarrhea caused by enterotoxigenic Escherichia coli (ETEC).’ The Naval Medical Research Command (NMRC) also presented a poster at the symposium on the new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) developed in collaboration with Immuron. The NMRC poster is entitled ‘Research and Development of Hyperimmune Bovine Colostrum Products for the Prevention of Travelers’ Diarrhea.’ Copies of the presentations are available on the Company’s website. https://www.immuron.com.au/product-science/ U.S. Department of Defense funds Naval Medical Research Command and Walter Reed Army Institute of Research development of enhanced formulations of Travelan® The U.S. Department of Defense has funded a new program for the Naval Medical Research Command and Walter Reed Army Institute of Research to develop enhanced formulations of Travelan® potentially expanding the coverage of the product as a therapeutic against endemic military relevant diarrheal pathogens. This work will utilize the extensive experience of the U.S. Department of Defense human infectious disease vaccine programs and will target key protective antigens of the major enteric bacterial pathogens Campylobacter, Shigella and Enterotoxigenic E. coli strains not present in the current product formulation. Immuron will negotiate a sub award for this new collaboration with NMRC and WRAIR to advance this research. Immuron Limited Consolidated statement of profit or loss and other comprehensive income For the year ended 30 June 2024 Notes 2024 $ 2023 $ Revenue from contracts with customers Cost of goods sold Gross profit 1 4,902,865 (1,566,068) 3,336,797 1,804,705 (495,558) 1,309,147 Other income Fair value gains/(losses) to financial assets Net foreign exchange gains/(losses) Movement in inventory provision 2(a) 3(c) 3,408,199 (557,676) (27,603) - 2,591,498 (523,666) 363,724 430,932 General and administrative expenses Research and development expenses Selling and marketing expenses Operating loss 2(b) 2(b) 2(b) (4,555,726) (5,375,461) (2,029,648) (5,801,118) (4,220,905) (2,592,145) (927,423) (3,568,838) 327,756 (7,576) 320,180 116,323 (9,652) 106,671 (1,456,019) (6,936,957) (324,340) (3,786,507) (6,936,957) (3,786,507) 2,266 (6,934,691) (1,012) (3,787,519) Cents Cents (3.04) (1.66) Finance income Finance expenses Finance costs - net 5(b) Share of loss from associates Loss before income tax Income tax expense Loss for the year Other comprehensive income Items that may be reclassified to profit or loss: Exchange differences on translation of foreign operations Total comprehensive loss for the year Loss per share for loss attributable to the ordinary equity holders of the company: Basic and diluted loss per share 4(b) The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes. Immuron Limited 4 Immuron Limited Consolidated balance sheet As at 30 June 2024 2024 $ 2023 $ 11,657,315 1,387,573 1,584,608 96,841 14,726,337 17,159,764 417,420 839,968 1,834,034 158,151 20,409,337 154,347 669,285 823,632 159,066 200,133 1,219,646 1,578,845 Total assets 15,549,969 21,988,182 LIABILITIES Current liabilities Trade and other payables Employee benefit obligations Other current liabilities Deferred income Total current liabilities 2,135,852 522,571 40,556 2,698,979 1,192,769 289,408 38,767 698,195 2,219,139 8,605 132,941 141,546 1,882 150,325 152,207 Total liabilities 2,840,525 2,371,346 Net assets 12,709,444 19,616,836 88,504,043 3,173,797 (78,968,396) 88,436,263 3,235,969 (72,055,396) 12,709,444 19,616,836 Notes ASSETS Current assets Cash and cash equivalents Trade and other receivables Inventories Financial assets Other current assets Total current assets 3(a) 3(b) 3(c) Investments accounted for using the equity method Property, plant and equipment Inventories Total non-current assets 5(b) 3(d) Non-current liabilities Employee benefit obligations Other non-current liabilities Total non-current liabilities EQUITY Share capital Other reserves Accumulated losses 4(a) 4(b) Total equity The above consolidated balance sheet should be read in conjunction with the accompanying notes. Immuron Limited 5 Immuron Limited Consolidated statement of changes in equity For the year ended 30 June 2024 Notes Balance at 1 July 2023 Attributable to owners of Immuron Limited Accumulated Share capital Other reserves losses $ $ $ 88,436,263 3,235,969 (72,055,396) 19,616,836 - 2,266 2,266 (6,936,957) (6,936,957) (6,936,957) 2,266 (6,934,691) - 15,231 - 15,231 67,780 67,780 (11,932) (43,780) (23,957) (64,438) 23,957 23,957 (11,932) 24,000 27,299 88,504,043 3,173,797 (78,968,396) 12,709,444 Attributable to owners of Immuron Limited Accumulated Share capital Other reserves losses $ $ $ Total equity $ Loss for the year Other comprehensive income Total comprehensive income/(loss) for the year Transactions with owners in their capacity as owners: Unlisted options vested in the period Options and warrants issued/expensed (net of adjustments) Options and warrants exercised Options and warrants forfeited 4(b) 4(b) Balance at 30 June 2024 Balance at 1 July 2022 88,436,263 3,166,419 (68,425,281) 23,177,401 - (1,012) (1,012) (3,786,507) (3,786,507) (3,786,507) (1,012) (3,787,519) - 104,753 (156,392) 122,201 70,562 156,392 156,392 104,753 122,201 226,954 88,436,263 3,235,969 (72,055,396) 19,616,836 Loss for the year Other comprehensive loss Total comprehensive loss for the year Transactions with owners in their capacity as owners: Options and warrants issued/expensed (net of adjustments) Options and warrants lapsed/expired Performance rights issued/expensed Balance at 30 June 2023 Total equity $ The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes. Immuron Limited 6 Immuron Limited Consolidated statement of cash flows For the year ended 30 June 2024 2024 $ 2023 $ 4,734,350 (12,910,753) 395,001 1,901,263 (5,880,139) 1,912,689 (7,842,052) 251,986 3,082,182 (2,595,195) Cash flows from investing activities Payments for property, plant and equipment Payment for acquisition of associate Interest received Net cash inflow (outflow) from investing activities (195) 327,756 327,561 (7,739) (2,729,863) 116,323 (2,621,279) Cash flows from financing activities Proceeds from issues of shares Principal elements of lease payments Interest and other costs of finance paid Net cash inflow (outflow) from financing activities 24,000 (15,595) (7,576) 829 (35,015) (9,652) (44,667) (5,551,749) 17,159,764 49,300 11,657,315 (5,261,141) 22,110,278 310,627 17,159,764 Notes Cash flows from operating activities Receipts from customers Payments to suppliers and employees Australian R&D tax incentive refund Grants received from government and non-government sources Net cash (outflow) from operating activities Net (decrease) in cash and cash equivalents Cash and cash equivalents at the beginning of the financial year Effects of exchange rate changes on cash and cash equivalents Cash and cash equivalents at end of year 3(a) The above consolidated statement of cash flows should be read in conjunction with the accompanying notes. Immuron Limited 7 Immuron Limited Notes to the financial statements 30 June 2024 1 Revenue from contract with customers (a) Disaggregation of revenue from contracts with customers The group derives revenue from the transfer of hyperimmune products at a point in time in the following major product lines and geographical regions: 2024 Hyperimmune products revenue Revenue from external customers 2023 Hyperimmune products revenue Revenue from external customers Australia $ Travelan United States Protectyn $ Australia $ Total $ Canada 3,702,876 3,702,876 1,075,614 1,075,614 80,888 80,888 43,487 43,487 4,902,865 4,902,865 Australia $ Travelan United States $ Canada $ Australia $ Total $ 1,100,725 1,100,725 642,819 642,819 1,201 1,201 59,960 59,960 1,804,705 1,804,705 $ Protectyn 2 Other income and expense items (a) Other income Australian R&D tax incentive refund MTEC R&D grant Other income EMDG grant 2024 $ 2023 $ 764,981 2,599,458 15,760 28,000 3,408,199 392,877 2,158,936 11,685 28,000 2,591,498 (i) Fair value of R&D tax incentive The group's research and development (R&D) activities are eligible under an Australian government tax incentive for eligible expenditure. Management has assessed these activities and expenditure to determine which are likely to be eligible under the incentive scheme. Amounts are recognised when it has been established that the conditions of the tax incentive have been met and that the expected amount can be reliably measured. For the year ended 30 June 2024, the group has included an item in other income of $764,981 (2023: $392,877). Immuron Limited 8 Immuron Limited Notes to the financial statements 30 June 2024 (continued) 2 Other income and expense items (continued) (b) Breakdown of expenses by nature General and administrative expenses Accounting and audit Bad debts Consulting Depreciation Employee benefits Expected credit losses gain/(expense) Insurance Investor relations Legal Listing and share registry Occupancy Share-based payments expense Superannuation Travel and entertainment Other Research and development expenses Consulting Project research and development Selling and marketing expenses Selling Marketing Distribution costs 2024 $ 2023 $ 576,540 120,851 45,981 2,353,625 (11,687) 321,679 206,300 195,971 163,949 24,122 3,299 180,092 196,369 178,635 4,555,726 657,970 2,376 23,241 48,662 1,874,963 19,111 434,699 194,754 233,243 152,954 226,954 141,539 105,535 104,904 4,220,905 277,128 5,098,333 5,375,461 111,530 2,480,615 2,592,145 379,406 1,310,979 339,263 2,029,648 192,878 474,926 259,619 927,423 2024 $ 2023 $ 11,657,315 17,159,764 3 Financial assets and financial liabilities (a) Cash and cash equivalents Current assets Cash at bank and in hand (i) Classification as cash equivalents Term deposits are presented as cash equivalents if they have a maturity of three months or less from the date of acquisition and are repayable with 24 hours notice with no loss of interest. Immuron Limited 9 Immuron Limited Notes to the financial statements 30 June 2024 (continued) 3 Financial assets and financial liabilities (continued) (b) Trade and other receivables Notes Trade receivables Loss allowance Accrued income - Australian R&D tax incentive refund Other income receivables - R&D grants Total trade and other receivables Current $ 2023 Noncurrent $ Total $ 607,436 (16,233) 591,203 46,949 (27,920) 19,029 - 46,949 (27,920) 19,029 - 768,370 398,391 - 398,391 28,000 796,370 - 28,000 796,370 398,391 - 398,391 1,387,573 - 1,387,573 417,420 - 417,420 Current $ 2024 Noncurrent $ Total $ 607,436 (16,233) 591,203 - 768,370 (i) Classification as trade receivables Trade receivables are amounts due from customers for goods sold or services performed in the ordinary course of business. They are generally due for settlement within 30 days and therefore are all classified as current. Trade receivables are recognised initially at the amount of consideration that is unconditional unless they contain significant financing components, when they are recognised at fair value. The group holds the trade receivables with the objective to collect the contractual cash flows and therefore measures them subsequently at amortised cost using the effective interest method. (ii) Accrued receivables These amounts primarily comprise receivables from the Australian Taxation Office in relation to the R&D tax incentive. (iii) Fair value of trade and other receivables Due to the short-term nature of the current receivables, their carrying amount is considered to be the same as their fair value. Immuron Limited 10 Immuron Limited Notes to the financial statements 30 June 2024 (continued) 3 Financial assets and financial liabilities (continued) (c) Financial assets The group classifies the following as financial assets recognised at fair value through profit or loss (FVPL) as part of Immuron's strategic investment in Ateria: • Immuron was entitled to 735,000 share options with a total exercise price of £1,470,000 that expired on 31 July 2023. Immuron elected not to exercise 735,000 share options during the period ending 30 June 2024. • Immuron received to 471,306 shares as Ateria consideration based on performance targets. Financial assets mandatorily measured at FVPL include the following: 2024 $ 2023 $ - 221,620 1,612,414 1,834,034 2024 $ 2023 $ (557,676) (523,666) Current assets Ateria share options Ateria contingent shares (i) Amounts recognised in profit or loss During the year, the following losses were recognised in profit or loss: Fair value gains/(losses) to financial assets Reconciliation Balance at 1 July 2023 Fair value gains/(losses) to financial assets Net foreign exchange gains Fair value at 22 February 2024 Share of the loss in Ateria for the period Issue of Ateria contingent shares Balance at 30 June 2024 Note Ateria share options $ 221,620 (221,620) - 5(b)(i) - Ateria contingent shares $ 1,612,414 (336,056) 20,595 1,296,953 (101,603) (1,195,350) - Total $ 1,834,034 (557,676) 20,595 1,296,953 (101,603) (1,195,350) - On 22 February 2024, Immuron received 471,306 shares in Ateria Health upon satisfying performance milestones. Immuron Limited 11 Immuron Limited Notes to the financial statements 30 June 2024 (continued) 3 Financial assets and financial liabilities (continued) (d) Deferred income Current liabilities Other deferred income 2024 $ 2023 $ - 698,195 4 Equity (a) Share capital 2024 Shares 2023 Shares 2024 $ 2023 $ 227,998,346 227,998,346 227,798,346 227,798,346 88,504,043 88,504,043 88,436,263 88,436,263 Number of shares Total $ 227,798,346 88,436,263 - - 227,798,346 88,436,263 200,000 - 67,780 - 227,998,346 88,504,043 Notes Ordinary shares Fully paid (i) 4(a)(i) Movements in ordinary shares: Details Balance at 1 July 2022 Less: Transaction costs arising on share issues Balance at 30 June 2023 Issue at $0.12 on exercise of unlisted options (2024-03-12) Less: Transaction costs arising on share issues Balance at 30 June 2024 Immuron Limited 12 Immuron Limited Notes to the financial statements 30 June 2024 (continued) 4 Equity (continued) (a) Share capital (continued) (ii) Ordinary shares Ordinary shares entitle the holder to participate in dividends, and to share in the proceeds of winding up the company in proportion to the number of and amounts paid on the shares held. On a show of hands every holder of ordinary shares present at a meeting in person or by proxy, is entitled to one vote, and upon a poll each share is entitled to one vote. Ordinary shares have no par value and the company does not have a limited amount of authorised capital. (b) Other reserves The following table shows a breakdown of the consolidated balance sheet line item ‘other reserves’ and the movements in these reserves during the year. A description of the nature and purpose of each reserve is provided below the table. Notes At 1 July 2022 Currency translation differences Other comprehensive income Transactions with owners in their capacity as owners Options and warrants vested Options and warrants issued/expensed Options and warrants lapsed/expired At 30 June 2023 4(b)(ii) 4(b)(ii) 4(b)(ii) Notes At 1 July 2023 Currency translation differences Other comprehensive income Transactions with owners in their capacity as owners Options issued in the period (net of adjustments) Options and warrants exercised Options and warrants lapsed/expired Options and warrants vested At 30 June 2024 4(b)(ii) 4(b)(ii) 4(b)(ii) Immuron Limited Share-based payments $ Foreign currency translation $ Total other reserves $ 3,053,197 113,222 3,166,419 - (1,012) (1,012) (1,012) (1,012) 122,201 104,753 (156,392) 3,123,759 112,210 122,201 104,753 (156,392) 3,235,969 Share-based payments $ Foreign currency translation $ Total other reserves $ 3,123,759 112,210 3,235,969 - 2,266 2,266 2,266 2,266 (11,932) (43,780) (23,957) 15,231 3,059,321 114,476 (11,932) (43,780) (23,957) 15,231 3,173,797 13 Immuron Limited Notes to the financial statements 30 June 2024 (continued) 4 Equity (continued) (b) Other reserves (continued) (i) Nature and purpose of other reserves Share-based payments The share-based payment reserve records items recognised as expenses on valuation of share options and warrants issued to key management personnel, other employees and and eligible contractors. Foreign currency translation Exchange differences arising on translation of foreign controlled entities are recognised in other comprehensive income as described in note and accumulated in a separate reserve within equity. The cumulative amount is reclassified to profit or loss when the net investment is disposed of. (ii) Movements in options, warrants and performance rights: Number of options or performance rights Total $ Balance at 1 July 2022 19,873,877 3,053,197 Share-based payments expenses - options Lapse of unexercised options Performance rights issued/expensed (i) 1,430,000 (8,424,157) - 104,753 (156,392) 122,201 Balance at 30 June 2023 12,879,720 3,123,759 1,000,000 (200,000) (173,600) 1,688,839 (11,93